From hope to reality: the road to cure from multiple myeloma centers of excellence
DOI:
https://doi.org/10.35509/01239015.989Resumen
Multiple myeloma (MM) is a heterogeneous disease that until now has been considered incurable, even in the younger population (1,2). However, recent data show an increase in the number of MM patients who have achieved what is called an “operational cure” due to innovative treatments and diagnostic and follow-up alternatives, something that has become a hope in oncologic hematology (3,4). The strategies that have been determinant in the improvement of survival and quality of life in most patients are the use of combined and targeted treatment modalities from the onset of the disease, especially in patients at high biological risk (4-6), high-dose chemotherapy, and autologous stem cell transplantation (ASCT) (7,8), which helped obtain deeper responses by achieving the negativization of minimal residual disease (MRD), continuous therapy to control MRD when it persists (9), improved techniques for early detection of relapses (6), the use of novel therapies in relapse cases, especially immune effector cell therapy (8), and finally the possibility of access to novel drugs in the context of standard of care or clinical trials (10).
The Instituto Nacional de Cancerología (INC) (Bogotá, Colombia)—an accredited health institution whose mission is to work for the integral control of cancer through the attention and care of patients, research, training of human talent, and the development of public health actions—has bet not only on the consolidation of functional cancer units but also on the attention of patients through centers of excellence (CE). In this regard, the Centro de Excelencia en Mieloma Múltiple del Instituto Nacional de Cancerología (CEMMINC) was a pioneer in the group of hematologic neoplasms (11). This CE is coordinated and run by professionals trained and dedicated exclusively to the care of MM and related diseases, a model that has been extraordinarily efficient in the best cancer centers in Canada, the United States, and Europe (12-15).
Referencias bibliográficas
Martinez-Cordero H, Peña C, Schutz NP, Bove V, Villano F, Osorio R, et al. Multiple myeloma patients aged 40 years and younger have the same prognosis as older patients in an analysis of real-world evidence from Latin America: A study of 1,316 patients from the GELAMM Latin American Multiple Myeloma Study Group. Blood. 2022;140(Supplement 1):7189-91. http://dx.doi.org/10.1182/blood-2022-158104
Ravi P, Kumar SK, Cerhan JR, Maurer MJ, Dingli D, Ansell SM, et al. Defining cure in multiple myeloma: a comparative study of outcomes of young individuals with myeloma and curable hematologic malignancies. Blood Cancer J. 2018;8(3):26. http://dx.doi.org/10.1038/s41408-018-0065-8
Takamatsu H. Guest Editorial: Innovation will be a bridge to cure in patients with multiple myeloma? Int J Hematol. 2022;115(6):760-1. http://dx.doi.org/10.1007/s12185-022-03371-3
Mohty M, Avet-Loiseau H, Harousseau JL. Requirements for operational cure in multiple myeloma. Blood. 2021;138(16):1406-11. http://dx.doi.org/10.1182/blood.2021012854
Fonseca R, Facon T, Hashim M, Nair S, He J, Ammann E, et al. Impact of treatment sequencing on overall survival in patients with transplant-ineligible newly diagnosed myeloma. Oncologist. 2023;28(5):e263-e269. http://dx.doi.org/10.1093/oncolo/oyad053
Mateos MV, Martínez BP, González-Calle V. High-risk multiple myeloma: how to treat at diagnosis and relapse? Hematology Am Soc Hematol Educ Program. 2021;2021(1):30-6. http://dx.doi.org/10.1182/hematology.2021000229
Richardson PG, Jacobus SJ, Weller EA, Hassoun H, Lonial S, Raje NS, et al. Triplet therapy, transplantation, and maintenance until progression in myeloma. N Engl J Med. 2022;387(2):132-47. http://dx.doi.org/10.1056/NEJMoa2204925
Shah UA, Mailankody S. Emerging immunotherapies in multiple myeloma. BMJ. 2020;370:m3176. http://dx.doi.org/10.1136/bmj.m3176
Dimopoulos MA, Jakubowiak AJ, McCarthy PL, Orlowski RZ, Attal M, Bladé J, et al. Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma. Blood Cancer J. 2020;10(2):17. http://dx.doi.org/10.1038/s41408-020-0273-x
Jung SH, Lee JJ, Song GY, Lee HS, Kim SJ, Yoon SE, et al. Clinical trial participation improves survival outcomes by increasing availability of new therapeutic agents in multiple myeloma. Br J Haematol. 2022;196(4):1117-20. http://dx.doi.org/10.1111/bjh.17898
Acreditación en Salud. Acreditado en salud el Instituto Nacional de Cancerología E.S.E. Accessed: June 18, 2023. Available from: https://acreditacionensalud.org.co/noticias/acreditado-en-salud-el-instituto-nacional-de-cancerologia-e-s-e/
The Princess Margaret Cancer Foundation. Accelerating multiple myeloma research. Accessed: June 19, 2023. Available from: https://thepmcf.ca/media-supporter-stories/latest-news/2023/accelerating-multiple-myeloma-research/
Mayo Clinic. Multiple myeloma: Rafael Fonseca. Accessed: June 19, 2023. Available from: https://www.mayo.edu/research/labs/multiple-myeloma-lab/overview
Mount Sinai Tisch Cancer Center. Center of Excellence for Multiple Myeloma. Accessed: June 19, 2023. Available from: https://www.mountsinai.org/care/cancer/services/multiple-myeloma
Hematología-Hospital Universitario Salamanca. Ensayos clínicos. Accessed: June 19, 2023. Available from: https://hematosalamanca.es/ensayos-clinicos/
Global Multiple Myeloma Academy. Treating multiple myeloma in Latin America and Canada. Emerging and practical concepts in multiple myeloma. Accessed: June 19, 2023. Available from: https://globalmmacademy.com/meeting-2
Martinez-Codero H, Martínez LM, Ospina Idárraga JA, Ruiz Argüelles G, Abello Polo V, Peña Ojeda C, et al. Consenso del Grupo Latinoamericano de Estudio de Mieloma Múltiple (MM) GELAMM para el manejo del MM en estado de pandemia SARS CoV-2 / COVID 19: Recomendaciones basadas en consenso de expertos. Rev Colomb Cancerol. 2020;24(Suplemento 1). http://dx.doi.org/10.35509/01239015.656
Instituto Nacional de Cancerología (INC). Anuario estadístico 2021. Bogotá: INC; 2022. Available from: https://www.cancer.gov.co/recursos_user/files/libros/archivos/Anuario_Estadi%CC%81sticoINC_2021.pdf
López-Mora DA, Carrió I, Flotats A. Digital PET vs analog PET: clinical implications? Semin Nucl Med. 2022;52(3):302-11. http://dx.doi.org/10.1053/j.semnuclmed.2021.10.004
Instituto Nacional de Cancerología. Grupo de investigación en mieloma múltiple y linfomas. Accessed: June 19, 2023. Available from: https://www.cancer.gov.co/centro-investigacion/grupos-reconocidos-minciencias-scienti/grupo-investigacion-mieloma-multiple
Gómez Mier LC, Salinas Alvarez V, Ras El Abiad A, Soto Montoya C, Martínez Cordero H. Analysis of clinical characteristics and survival of Multiple myeloma patients with fractures. Blood. 2020;136(Supplement 1):17. http://dx.doi.org/10.1182/blood-2020-138570
Martínez Cordero H, Peña C, Fantl D, Riva E, Schutz NP, Abello V, et al. Sars CoV-2/COVID-19 in multiple myeloma Latin-American patients COVID-Lamm study on behalf of Gelamm (Grupo de Estudio Latino-Americano de Mieloma Múltiple). Blood. 2020;136(Supplement 1):24-6. http://dx.doi.org/10.1182/blood-2020-142823
Peña C, Riva E, Schutz N, Tarín-Arzaga L, Martínez-Cordero H, Bove V, et al. Different outcomes for transplant-eligible newly diagnosed multiple myeloma patients in Latin America according to the public versus private management: a GELAMM study. Leuk Lymphoma. 2020;61(13):3112-9. http://dx.doi.org/10.1080/10428194.2020.1804558
Peña C, Riva E, Schutz N, Ramírez A, Vásquez J, Del Carpio D, et al. Primary plasma cell leukemia in Latin America: demographic, clinical, and prognostic characteristics. A study of GELAMM group. Leuk Lymphoma. 2023;64(4):816-21. http://dx.doi.org/10.1080/10428194.2023.2171266
Abello V, Sossa-Melo C, Idrobo H, Munevar I, Quintero G, Mantilla W, et al. PB1978: autologous stem cell transplantation and maintenance improves survival in Colombian multiple myeloma patients. ACHO’S RENEHOC registry report. Hemasphere. 2022;6(Suppl):1851-2. http://dx.doi.org/10.1097/01.HS9.0000850748.95462.8b
Garrido D, Slavutsky I, Riva E; Grupo de Estudio Latinoamericano de Mieloma Múltiple (GELAMM). Survival analysis of transplant-eligible newly-diagnosed multiple myeloma patients harboring t(4;14), t(14;16), and/or del(17p) in the real-world setting. Curr Probl Cancer. 2023;47(1):100916. http://dx.doi.org/10.1016/j.currproblcancer.2022.100916
Martínez Cordero H, Zapata Malagon J, Cubillos Osorio L, Rico Mendoza A, Porras Ramírez A, Ospina Idarraga J, et al. Multiple Myeloma mortality incidence prevalence of disease - Mmy Mind study. Blood. 2020;136(Supplement 1):10-1. http://dx.doi.org/10.1182/blood-2020-142376
Riva E, Duarte PJ, Valcárcel B, Remaggi G, Murrieta I, Corzo A, et al. Treatment and survival outcomes of Waldenstrom macroglobulinemia in Latin American patients: a multinational retrospective cohort study. JCO Glob Oncol. 2022;8:e2100380. http://dx.doi.org/10.1200/GO.21.00380
Riva E, Tietsche de Moraes Hungría V, Chiattone C, Martínez-Cordero H. Management of Waldenström macroglobulinemia in limited-resource settings. Hematol Oncol Clin North Am. 2023:S0889-8588(23)00044-8. http://dx.doi.org/10.1016/j.hoc.2023.04.010
European Hematology Association (EHA). Abstract. PB2058. Light-chain amyloidosis in Latin America. Diagnosis and frontline treatment. Accessed: June 18, 2023. Available from: https://library.ehaweb.org/eha/2020/eha25th/297974/elosa.riva.light-chain.amyloidosis.in.latin.america.diagnosis.and.frontline.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Ac_id%3D297974
Cómo citar
Descargas
Descargas
Publicado
Número
Sección
Licencia
Derechos de autor 2023 Revista Colombiana de Cancerología
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.
Todos los derechos reservados.
